6 results
RIPE Therapy - Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis - IDSA Guidelines

#Tuberculosis #ActiveTB #RIPE #Therapy
RIPE Therapy - Drug ... Microbiologically Confirmed Pulmonary ... #ActiveTB #RIPE ... Therapy #regimens #medications ... #Guidelines #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
inhibitors • Injection drug ... • HIV: 2/3 pulmonary ... Treatment: Active ... Initiating Treatment ... Diagnosis #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
inhibitors • Injection drug ... • HIV: 2/3 pulmonary ... Treatment: Active ... Initiating Treatment ... Diagnosis #Management #Treatment
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... Mycobacterium Tuberculosis ... prevent TB disease) Indications ... Mycobacterium #Tuberculosis ... #TB #IDSA #Prevention
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
IDSA Recommendations ... Prophylaxis): Indications ... Note: Active TB ... AviumComplex #MAC #IDSA ... #Prevention #Treatment
Causes of Unintentional Weight Loss - Differential Diagnosis
Malignancy 
 - Tumor effect* (esp. Gl, lung, lymphoma)
lymphoma) - Treatment ... Infections: HIV/AIDS, Tuberculosis ... cachexia"), COPD ("pulmonary ... cachexia") Medications ... GLP-I agonists Drugs